New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

Cardiovascular Business October 27, 2024
Michael Walter

HeartFlow, a California-based healthcare technology company known for its non-invasive artificial intelligence (AI) technologies, has shared new seven-year data demonstrating the long-term impact of its AI-powered FFR_CT Analysis and Plaque Analysis offerings.

The data were presented Sunday, Oct. 27, on the opening day of TCT 2024 in Washington D.C.

First, researchers shared data from the ADVANCE-DK study, a subanalysis of the larger ADVANCE registry, that confirmed FFR_CT Analysis and Plaque Analysis can help care teams anticipate when coronary artery disease (CAD) patients may face future adverse cardiovascular events. A prior three-year update had found that patients with abnormal FFR_CT and high plaque burden were much more likely to experience an adverse event than patients with only abnormal FFR_CT findings or...

Today's Sponsors

Today's Sponsor